Physician profile

Umar Latif

Psychiatry · Cross Roads, TX

NPI 1952413510

$329.75

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$21.84

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $145.13 2019-2022
Alkermes, INC. $29.48 2021
Abbvie INC. $29.32 2022
Neurocrine Biosciences, INC. $25.73 2021
Allergan, INC. $23.75 2020
Biogen, INC. $22.46 2021
Takeda Pharmaceuticals U.S.A., INC. $21.84 2023 Trintellix
Otsuka America Pharmaceutical, INC. $16.96 2022
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $15.08 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Umar Latif

$329.75

in general payments reported 2019-2025

Years
2019-2023
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/43455/umar-latif

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.